Original Articles

Xuefu Zhuyu capsule (血府逐瘀胶囊) modulates angiogenesis in association with the Jagged1/Notch pathway in lung cancer and chemotherapy contexts

  • WANG Yizheng ,
  • ZHANG Jiayu ,
  • LI Yuxia ,
  • FU Juanli ,
  • PING Chunjia ,
  • LI Yuxuan ,
  • WANG He ,
  • GAO Dong ,
  • LIN Fan
Expand
  • 1 College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China
    2 Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China

WANG Yizheng and ZHANG Jiayu are co-first authors and contributed equally to this work

LIN Fan, College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China; Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China. 2009037@fjtcm.edu.cn,Telephone: +86-591-22861151

Received date: 2025-08-12

  Accepted date: 2025-12-23

  Online published: 2026-10-09

Supported by

National Natural Science Foundation of China: Mechanism of Xuefu Zhuyu Decoction Regulating Vascular Growth of Lung Cancer with Qi Stagnation and Blood Stasis through Delta-like Protein 4/Notch Signaling Pathway(82204969);Role and Mechanism of Krüppel-like Factor 2 Signaling in Promoting Angiogenesis by Xuefu Zhuyu Decoction under Fluid Shear Stress(82074191);Study on the Mechanism of Krüppel-like Factor 4/5 as a Molecular Switch in the Angiogenesis Signaling Network of Xuefuzhuyu Decoction(82304954);Natural Science Foundation of Fujian Province: the Role of Fructose-2, 6-bisphosphatase 3-Mediated Glycolysis in the Overall Regulation of Angiogenesis by Xuefu Zhuyu Decoction(2024J01748)

Abstract

OBJECTIVE: To elucidate the regulatory effect of Xuefu Zhuyu capsule (血府逐瘀胶囊, XFZYC) on angiogenesis in the contexts of lung cancer and chemotherapy, and to investigate its correlation with the Jagged1/Notch signaling pathway.

METHODS: A Lewis lung carcinoma (LLC) tumor-bearing mouse model was established and treated with XFZYC and cisplatin (DDP) for two weeks. Tumor growth was monitored, immunohistochemistry was employed to assess microvessel density in tumor tissues, laser speckle contrast imaging was used to evaluate tumor blood perfusion, and Western blotting was performed to examine the expression of Jagged1/Notch signaling pathway-related proteins. In vitro, a co-culture system of LLC cells and vascular endothelial cells (C166) was used to quantify angiogenesis-related factors in the supernatant after XFZYC drug-containing serum (XFZY-CS) or DDP treatment, followed by tube formation assays to assess C166 angiogenic capacity. Additionally, a stable Jagged1-overexpressing C166 cell line was generated to evaluate drug-mediated regulation of tube formation under chemotherapy conditions.

RESULTS: In vivo results demonstrated that XFZYC combined with DDP significantly suppressed tumor growth in lung cancer-bearing models (P < 0.01). Compared with the model group, the combination therapy group showed significantly reduced microvessel density and blood perfusion (P < 0.05); however, these parameters were significantly higher in the combination group than in the DDP-alone group (P < 0.05). Relative to the model group, the combination treatment inhibited Jagged1 and vascular endothelial growth factor receptor 2 (VEGFR2) protein expression (P < 0.05) while promoting Notch1 activation and Hey1 protein expression (P < 0.05). In contrast, the combination group exhibited significantly elevated Jagged1 and VEGFR2 expression along with increased Notch1 activation products compared to the DDP-alone group (P < 0.05). In vitro findings revealed that XFZY-CS inhibited tube formation of C166 cells (P < 0.05) and reduced secretion of vascular endothelial growth factor A(VEGFA), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF) as well as Jagged1 protein expression in endothelial cells under lung cancer and chemotherapy conditions (P < 0.05). Notably, following Jagged1 overexpression, XFZY-CS failed to modulate the tube formation ability of C166 cells.

CONCLUSION: In lung cancer and chemotherapy settings, XFZYC moderately suppresses tumor angiogenesis, a process that is associated with the Jagged1/Notch signaling pathway.

Cite this article

WANG Yizheng , ZHANG Jiayu , LI Yuxia , FU Juanli , PING Chunjia , LI Yuxuan , WANG He , GAO Dong , LIN Fan . Xuefu Zhuyu capsule (血府逐瘀胶囊) modulates angiogenesis in association with the Jagged1/Notch pathway in lung cancer and chemotherapy contexts[J]. Journal of Traditional Chinese Medicine, 2026 , 46(5) : 1106 -1116 . DOI: 10.19852/j.cnki.jtcm.2026.05.005

References

[1] Altorki NK, Markowitz GJ, Gao D, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer 2019; 19: 9-31.
[2] Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
[3] Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 2017; 20: 409-26.
[4] Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduction Targeted Ther 2023; 8: 198.
[5] Martin JD, Seano G, Jain RK. Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu Rev Physiol 2019; 81: 505-34.
[6] Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2019; 77: 1745-70.
[7] Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
[8] Nikmaneshi MR, Jain RK, Munn LL. Computational simulations of tumor growth and treatment response: benefits of high-frequency, low-dose drug regimens and concurrent vascular normalization. PLOS Comput Biol 2023; 19: e1011131.
[9] Qian Y, Wang X. Effects of blood-activating and stasis-resolving drugs on tumor formation and metastasis. J Tradit Chin Med 2009; 29: 301-10.
[10] Wu S, Sun Z, Guo Z, et al. The effectiveness of blood-activating and stasis-transforming Traditional Chinese Medicines (BAST) in lung cancer progression-a comprehensive review. J Ethnopharmacol 2023; 314: 116565.
[11] Yang C, Feng W, Zhu S. Clinical effect of advanced lung cancer treated by the Chinese herb named modified Xuefu Zhuyu decoction Jiawei combined with etoposide and cisplatin chemotherapy. Ai Zheng Jin Zhan 2020; 18: 1786-9.
[12] Yao H, Yao D. Modified Xuefu Zhuyu decoction combined with chemotherapy in the treatment of 45 cases of mid-to-late stage non-small cell lung cancer with Qi stagnation and blood stasis pattern. Hunan Zhong Yi Za Zhi 2021; 37: 57-60.
[13] Zhang X, Wang X. Short-term efficacy observation of Xuefu Zhuyu decoction combined with EP chemotherapy in the treatment of small cell lung cancer with lung collateral stasis obstruction pattern. Yatai Chuan Tong Yi Yao 2018; 14: 202-4.
[14] Gao D, Jiao Y, Wu Y. Experimental study of Xuefu Zhuyu decoction induced participation of endothelial progenitor cells in the angiogenesis of the ischemic region. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2012; 32: 224-8.
[15] Chen CH, Chen MC, Hsu YH, Chou TC. Far-infrared radiation alleviates cisplatin-induced vascular damage and impaired circulation via activation of HIF-1α. Cancer Sci 2022; 113: 2194-206.
[16] Soultati A, Mountzios G, Avgerinou C, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev 2012; 38: 473-83.
[17] Benedito R, Roca C, Sörensen I, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009; 137: 1124-35.
[18] Oon CE, Bridges E, Sheldon H, et al. Role of delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth. Oncotarget 2017; 8: 40115-31.
[19] Wang Y, Lin F, Cai F. Effect of Xuefu Zhuyu capsule in regulating Jagged1/Notch signal in angiogenesis. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2017; 23: 132-6.
[20] Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017; 117: 219-30.
[21] Streiff MB, Holmstrom B, Angelini D, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Cancer Netw 2018; 16: 1289-303.
[22] Zhang Y, Zhang X, Ye L. Commonly-used compatibility of medicines with the funcion of promoting blood circulation for removing blood stasis and its clinical application in treating cancer. Nanjing Zhong Yi Yao Da Xue Xue Bao 2013; 29: 305-8.
[23] Zheng Q, Zhou T, Xiang S. Clinical study of Xuefu Zhuyu decoction in the treatment of pain from advanced lung cancer with Yuxuezuluo syndrome. Zhong Yao Yao Li Yu Lin Chuang 2022; 38: 195-8.
[24] Li T, Kang G, Wang T, Huang H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett 2018; 16: 687-702.
[25] Shah AA, Kamal MA, Akhtar S. Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions. Curr Drug Metab 2021; 22: 50-9.
[26] Peng R, Rong H, Ma X. Mechanism of angiogenesis effect by salviae miltiorrhizae radix and its preparations in ischemic heart disease. Zhong Guo Xian Dai Zhong Yao 2021; 23: 171-6.
[27] Yang T, Zhang L, Huang R. Research progress in the regulation of angiogenesis by active ingredients of Traditional Chinese Medicine. Yao Xue Xue Bao 2020; 55: 1995-2007.
[28] Zhang D, Chen L, Maryam M, Xue J, Liu P, Liu M. Application of promoting blood circulation and resolving blood stasis in intracerebral hemorrhage: a traditional method gradually being reconsidered. J Tradit Chin Med 2025; 45: 458-72.
[29] Xu Q, Yu Z, Zhang M, et al. Danshen-shanzha formula for the treatment of atherosclerosis: ethnopharmacological relevance, preparation methods, chemical constituents, pharmacokinetic properties, and pharmacological effects. Front Pharmacol 2024; 15: 1380977.
[30] Tao L, Wang S, Zhao Y, et al. Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis. Chin J Integr Med 2016; 22: 795-800.
[31] Song M, Men B, Chen M, et al. Exploration of the mechanism of Danggui Buxue decoction (当归补血汤) for the treatment of gastric ulcer based on network pharmacology, molecular docking, and experiment. J Tradit Chin Med 2025; 45: 806-16.
[32] Lin F, Chen BL, Wang YZ, et al. In vitro angiogenesis effect of Xuefu Zhuyu decoction (血府逐瘀) and vascular endothelial growth factor: a comparison study. Chin J Integr Med 2018; 24: 606-12.
[33] Zhang JS, Wang YZ, Hu YQ, et al. Effect of EphB4/EphrinB2 reverse signal on angiogenesis induced by Xuefu Zhuyu capsule (血府逐瘀胶囊) containing serum in human microvascular endothelial cell 1. Chin J Integr Med 2016; 22: 605-10.
[34] Zhao G, Zhang Y, Zhao Z, et al. MiR-153 reduces stem cell-like phenotype and tumor growth of lung adenocarcinoma by targeting Jagged1. Stem Cell Res Ther 2020; 11: 170.
[35] Alabi RO, Glomski K, Haxaire C, Weskamp G, Monette S, Blobel CP. ADAM10-dependent signaling through Notch1 and Notch4 controls development of organ-specific vascular beds. Circ Res 2016; 119: 519-31.
[36] Zhu G, Lin Y, Ge T, et al. A novel peptide inhibitor of Dll4-Notch1 signalling and its pro-angiogenic functions. Br J Pharmacol 2022; 179: 1716-31.
[37] Pedrosa AR, Trindade A, Fernandes AC, et al. Endothelial Jagged1 antagonizes Dll4 regulation of endothelial branching and promotes vascular maturation downstream of Dll4/Notch1. Arterioscler Thromb Vasc Biol 2015; 35: 1134-46.
[38] Ren R, Ding S, Ma K, et al. SUMOylation fine-tunes endothelial HEY1 in the regulation of angiogenesis. Circ Res 2024; 134: 203-22.
Outlines

/

〈 〉